Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

14 results
Display

Economic Evaluation of Iron Chelation Agents: Oral Deferasirox versus Infusional Deferoxamine

Kim JH, Kim YH

BACKGROUND: Patients with transfusional iron overload have relied on treatment with deferoxamine, a standard chelating agent. Deferoxamine is administered by intravenous or subcutaneous infusion over an 8~12 hour period 5~7...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Immune Responses Induced by Deferoxamine and Deferasirox

Jung YS, Bae EY, Chung NG, Cho B, Kim HK, Min CK, Han CW, Kim HS, Jeong DC

BACKGROUND: The iron chelating agents (ICA) have various biological effects besides iron chelation. We investigated the immunomodulatory effects of Deferasirox (DFS) compared to Deferoxamine (DFO). METHODS: Spleen cells (SP) were obtained...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Iron chelating agent, deferoxamine, induced apoptosis in Saos-2 osteosarcoma cancer cells

Park EH, Lee HJ, Lee SY, Kim SY, Yi HK, Lee DY, Hwang PH

PURPOSE: Iron is a critical nutritional element that is essential for a variety of important biological processes, including cell growth and differentiation, electron transfer reactions, and oxygen transport, activation, and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Guanosine 5′-monophosphate-chelated calcium and iron feed additives maintains egg production and prevents Salmonella Gallinarum in experimentally infected layers

Noh HJ, Kim H, Heo SJ, Cho HH, Koh HB

We evaluated the effects of guanosine 5′-monophosphate (GMP)-chelated calcium and iron (CaFe-GMP) on health and egg quality in layers experimentally infected with Salmonella Gallinarum. In this study, a CaFe-GMP feed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci

Kim CM, Shin SH

The standard iron-chelator deferoxamine is known to prevent the growth of coagulase-negative staphylococci (CoNS) which are major pathogens in iron-overloaded patients. However, we found that deferoxamine rather promotes the growth...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload

Jang JH, Lee JH, Yoon SS, Jo DY, Kim HJ, Chung J, Lee JW

Many Korean patients with transfusion-induced iron overload experience serious clinical sequelae, including organ damage, and require lifelong chelation therapy. However, due to a lack of compliance and/or unavailability of an...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Three Cases of Superficial Siderosis

Kim BG, Roh JK, Jeon BS, Han MH

  • KMID: 2342574
  • J Korean Neurol Assoc.
  • 1996 Sep;14(3):848-854.
Superficial siderosis is a rare condition characterized by hemosiderin deposition in leptomeninges, subpial tissue, brainstem, cerebellum, spinal cord, and cranial nerves. Slowly progressive hearing loss and gait ataxia are invariable...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recent advances in treatment of aplastic anemia

Shin SH, Lee SE, Lee JW

Recent advances in the treatment of aplastic anemia (AA) made most of patients to expect to achieve a long-term survival. Allogeneic stem cell transplantation (SCT) from HLA-matched sibling donor (MSD-SCT)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells

Kim DS, Na YJ, Kang MH, Yoon SY, Choi CW

BACKGROUND/AIMS: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diagnostic and Therapeutic Approach for Acute Paraquat Intoxication

Gil HW, Hong JR, Jang SH, Hong SY

Paraquat (PQ) has known negative human health effects, but continues to be commonly used worldwide as a herbicide. Our clinical data shows that the main prognostic factor is the time...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Complete Hematopoietic Recovery after Continuous Iron Chelation Therapy in a Patient with Severe Aplastic Anemia with Secondary Hemochromatosis

Park SJ, Han CW

A 16-yr-old male patient with hemochromatosis due to multiple packed red blood cell transfusions was referred to our emergency center for the treatment of severe aplastic anemia and dyspnea. He...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cost Analysis of Iron-Related Complications in a Single Institute

Kim KH, Kim JW, Rhee JY, Kim MK, Kim BS, Kim I, Bang SM, Yoon SS, Lee JS, Han KS, Park S, Kim BK

BACKGROUND/AIMS: The financial burden of caring for iron-related complications (IRCs) is an emerging medical problem in Korea, as in Western countries. We produced a preliminary estimate of the costs...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Iron Overload during Follow-up after Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma

Bae SJ, Kang C, Sung KW, Chueh HW, Son MH, Lee SH, Yoo KH, Koo HH

Multiple RBC transfusions inevitably lead to a state of iron overload before and after high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT). Nonetheless, iron status during post-SCT follow-up remains unknown....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Iron chelator inducesMIP-3alpha/CCL20 in human intestinal epithelial cells: implication for triggeringmucosal adaptive immunity

Lee HJ, Choi SC, Choi EY, Lee MH, Seo GS, Kim EC, Yang BJ, Lee MS, Shin YI, Park KI, Jun CD

  • KMID: 1093465
  • Exp Mol Med.
  • 2005 Aug;37(4):297-310.
A previous report by this laboratory demonstrated that bacterial iron chelator (siderophore) triggers inflammatory signals, including the production of CXC chemokine IL-8, in human intestinal epithelial cells (IECs). Microarray-based gene...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr